VDPVs case | Non-polio AFP case | Healthy population | ||
---|---|---|---|---|
Sex | Male | 11 (73.3) | 7 (46.7) | 7 (36.8) |
Female | 4 (26.7) | 8 (53.3) | 12 (63.2) | |
Age (Median ± interquartile range) | 1.1 ± 1.3 | 1.4 ± 1.8 | 3.9 ± 6.6 | |
OPV immunization history | 0 dose | 7 (46.7) | 2 (13.3) | 3 (15.8) |
1–2 dose | 3 (20.0) | 1 (6.7) | 2 (10.5) | |
≥3 dose | 5 (33.3) | 10 (66.7) | 4 (21.1) | |
Unknown | 0 (0.0) | 2 (13.3) | 10 (52.6) | |
Nucleotide substitution in VP1 region a | ≤10 | 7 (46.7) | 12 (80.0) | 9 (47.4) |
11–15 | 7 (46.7) | 2 (13.3) | 7 (36.8) | |
≥ 16 | 1 (6.7) | 1 (6.7) | 3 (15.8) | |
Serotypes of VDPVs a | Type 1 | 6 (40.0) | 3 (20.0) | 11 (57.9) |
Type 2 | 4 (26.7) | 10 (66.7) | 6 (31.6) | |
Type 3 | 3 (20.0) | 2 (13.3) | 2 (10.5) | |
Type 2 + 3 | 2 (13.3) | 0 (0.0) | 0 (0.0) |